Literature DB >> 6134167

Protecting poor metabolizers, a group at high risk of adverse drug reactions.

J R Idle, N S Oates, R R Shah, R L Smith.   

Abstract

Mesh：

Substances：

Year:  1983        PMID： 6134167     DOI： 10.1016/s0140-6736(83)92172-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Pharmacogenetics and drug metabolism: an Irish perspective.

Authors:  P Holland; M Barry; J Feely
Journal:  Ir J Med Sci       Date:  1991-02       Impact factor: 1.568

2.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

3.  Red wine contains a potent inhibitor of phenolsulphotransferase.

Authors:  J T Littlewood; V Glover; M Sandler
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

4.  Variability of plasma drug concentrations: some observations.

Authors:  D B Jack; M R Wilkins; M J Kendall; P E Hall
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Adverse effects from metoprolol are not generally associated with oxidation status.

Authors:  D W Clark; A K Morgan; H Waal-Manning
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

6.  Protecting the poor metaboliser--from what?

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

7.  Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.

Authors:  C H Gleiter; G Aichele; E Nilsson; N Hengen; K H Antonin; P R Bieck
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

8.  Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.

Authors:  N Feifel; K Kucher; L Fuchs; M Jedrychowski; E Schmidt; K H Antonin; P R Bieck; C H Gleiter
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation.

Authors:  G Karlaganis; A Küpfer; R Preisig
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.